MedTrace Logo

Sac-TMT Combined With Toripalimab for First-line Treatment of PD-L1 Positive a/mTNBC

NCT07244874 · Status: NOT_YET_RECRUITING · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 41

Last updated 2025-11-24

No results posted yet for this study

Summary

This study is aimed to evaluate the efficacy and safety of Sacituzumab Tirumotecan combined with Toripalimab for first-line treatment of PD-L1 positive unresectable Locally Advanced/metastatic triple negative breast cancer (a/mTNBC).

Conditions

  • TNBC - Triple-Negative Breast Cancer
  • PD-L1 Positive

Interventions

DRUG

Sacituzumab tirumotecan

5mg/kg, Q2W

DRUG

Toripalimab

240mg，Q3W

Sponsors & Collaborators

  • Southwest Hospital, China

    collaborator OTHER

  • Tianjin Medical University Cancer Institute and Hospital

    lead OTHER

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
FEMALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2025-12-01
Primary Completion
2028-01-30
Completion
2029-07-30

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07244874 on ClinicalTrials.gov